7JN Stock Chart & Stats
€0.03
-€0.02(-30.16%)
At close: 4:00 PM EST
€0.03
-€0.02(-30.16%)
Day’s Range― - ―
52-Week Range€0.02 - €0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€56.37M
Enterprise Value€46.23M
Total Cash (Recent Filing)€7.71M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding705,103,760
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory & Trial ReadinessRegulatory sign-off (MHRA) and an operational TOPICAL setup with multiple UK sites and a CRO materially reduce execution risk for the near-term readout. Ready-to-start infrastructure and an agreed supply arrangement with J&J create durable de-risking ahead of the interim summer 2026 data.
Strong Mechanistic Efficacy SignalRobust cytokine suppression in a controlled human LPS challenge demonstrates clear target engagement and a plausible mechanism for CRS prevention. Mechanism-driven efficacy evidence is a lasting fundamental asset that supports clinical translation, payer interest and partner negotiations beyond short-term market moves.
IP & Financial ConservatismOrphan status and long-dated patent protection provide structural exclusivity that can enhance future pricing, partner bargaining power and potential royalty streams. Combined with low leverage (no reported debt), this strengthens long-term strategic optionality for licensing or collaborating on later-stage investment.
Bears Say
Pre‑revenue LossesBeing pre-revenue with recurring operating losses is a durable fundamental constraint: it necessitates continual external funding, depresses returns on equity and limits reinvestment flexibility. Over time, sustained losses erode equity and increase susceptibility to dilution or unfavorable financing terms.
Limited Cash RunwayA runway only into 2027 creates a structural financing imperative for mid‑stage expansion. The company will likely need additional capital or licensing deals to fund pivotal studies and commercialization, increasing dilution risk and placing program timelines dependent on successful near-term fundraises or partner commitments.
Small Open‑Label Trial & Partner RelianceA small, open‑label single‑arm TOPICAL design limits the definitiveness of efficacy conclusions and will likely require confirmatory trials, extending development time and cost. Reliance on external partners for late‑stage development and commercialization further concentrates execution and monetization risk.
Poolbeg Pharma Ltd. News
7JN FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest stock price was €0.02 and its highest was €0.10 in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is €56.37M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 68 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.006.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 705,103,760 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in DE:7JN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
-55.47%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---